DB:MM3

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Merit Medical Systems

Executive Summary

Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy.


Snowflake Analysis

Reasonable growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Merit Medical Systems's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MM3's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

11.5%

MM3

1.3%

DE Medical Equipment

1.5%

DE Market


1 Year Return

-20.9%

MM3

19.1%

DE Medical Equipment

-1.8%

DE Market

Return vs Industry: MM3 underperformed the German Medical Equipment industry which returned 20.4% over the past year.

Return vs Market: MM3 underperformed the German Market which returned -0.7% over the past year.


Shareholder returns

MM3IndustryMarket
7 Day11.5%1.3%1.5%
30 Day3.0%-8.7%4.3%
90 Day42.0%16.6%25.1%
1 Year-20.9%-20.9%20.6%19.1%0.2%-1.8%
3 Year23.3%23.3%112.7%108.2%1.3%-6.9%
5 Year113.1%113.1%253.5%239.0%15.0%-0.2%

Price Volatility Vs. Market

How volatile is Merit Medical Systems's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Merit Medical Systems undervalued compared to its fair value and its price relative to the market?

2.65x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: MM3 (€40.2) is trading above our estimate of fair value (€35.38)

Significantly Below Fair Value: MM3 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: MM3 is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: MM3 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MM3's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MM3 is good value based on its PB Ratio (2.7x) compared to the DE Medical Equipment industry average (4.6x).


Next Steps

Future Growth

How is Merit Medical Systems forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

107.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MM3 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).

Earnings vs Market: MM3 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MM3's is expected to become profitable in the next 3 years.

Revenue vs Market: MM3's revenue (7% per year) is forecast to grow faster than the German market (5.8% per year).

High Growth Revenue: MM3's revenue (7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MM3's Return on Equity is forecast to be low in 3 years time (8.6%).


Next Steps

Past Performance

How has Merit Medical Systems performed over the past 5 years?

-3.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MM3 is currently unprofitable.

Growing Profit Margin: MM3 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MM3 is unprofitable, and losses have increased over the past 5 years at a rate of -3.9% per year.

Accelerating Growth: Unable to compare MM3's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MM3 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (8.2%).


Return on Equity

High ROE: MM3 has a negative Return on Equity (-0.41%), as it is currently unprofitable.


Next Steps

Financial Health

How is Merit Medical Systems's financial position?


Financial Position Analysis

Short Term Liabilities: MM3's short term assets ($462.5M) exceed its short term liabilities ($165.3M).

Long Term Liabilities: MM3's short term assets ($462.5M) do not cover its long term liabilities ($644.2M).


Debt to Equity History and Analysis

Debt Level: MM3's debt to equity ratio (47.9%) is considered high.

Reducing Debt: MM3's debt to equity ratio has reduced from 48% to 47.9% over the past 5 years.

Debt Coverage: MM3's debt is well covered by operating cash flow (20.7%).

Interest Coverage: MM3 is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet


Next Steps

Dividend

What is Merit Medical Systems's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MM3's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MM3's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MM3's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MM3's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MM3's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.8yrs

Average management tenure


CEO

Fred Lampropoulos (70yo)

33yrs

Tenure

US$5,049,286

Compensation

Mr. Fred P. Lampropoulos has been the President of BioSphere Medical, Inc. since September 2010. Mr. Lampropoulos serves as the Chairman and Chief Executive Officer of Merit Medical Systems Inc. He has bee ...


CEO Compensation Analysis

Compensation vs Market: Fred's total compensation ($USD5.05M) is above average for companies of similar size in the German market ($USD2.41M).

Compensation vs Earnings: Fred's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Fred Lampropoulos
Chairman33yrsUS$5.05m1.92% $42.6m
Raul Parra
CFO & Treasurer2.17yrsUS$1.17m0.0053% $116.7k
Ronald Frost
Chief Operating Officer6.5yrsUS$1.23m0.038% $852.3k
Justin Lampropoulos
Executive Vice President of Commercial1.92yrsUS$1.21mno data
Joseph Wright
President of International Division5yrsUS$1.47m0.018% $400.0k
Jason Treft
Chief Technology Officerno datano datano data
Joseph Pierce
Chief Information Officer14.5yrsno datano data
Brian Lloyd
Chief Legal Officer & Corporate Secretary4.25yrsUS$1.20m0.00021% $4.7k
Anne-Marie Wright
Vice President of Corporate Communicationsno datano datano data
Louise Bott
Vice President of Global Human Resources13.5yrsno datano data

5.8yrs

Average Tenure

54yo

Average Age

Experienced Management: MM3's management team is seasoned and experienced (5.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Fred Lampropoulos
Chairman33yrsUS$5.05m1.92% $42.6m
Aldon Anderson
Independent Director8.67yrsUS$329.90k0.034% $750.4k
James Hogan
Independent Director0.083yrno datano data
David Floyd
Independent Director0.083yrno data0.00077% $17.1k
F. Millner
Independent Director5yrsUS$329.90k0.020% $449.2k
Jill Anderson
Director1.5yrsUS$469.83k0.012% $256.0k
Thomas Gunderson
Independent Director3.17yrsUS$329.90kno data
Lonny Carpenter
Independent Director0.083yrno data0.00067% $14.8k
Lynne Ward
Independent Director0.92yrUS$187.15kno data

1.5yrs

Average Tenure

64yo

Average Age

Experienced Board: MM3's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Merit Medical Systems, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Merit Medical Systems, Inc.
  • Ticker: MM3
  • Exchange: DB
  • Founded: 1987
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$2.490b
  • Listing Market Cap: US$2.215b
  • Shares outstanding: 55.38m
  • Website: https://www.merit.com

Number of Employees


Location

  • Merit Medical Systems, Inc.
  • 1600 West Merit Parkway
  • South Jordan
  • Utah
  • 84095
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MMSINasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 1990
MM3DB (Deutsche Boerse AG)YesCommon StockDEEURMay 1990

Biography

Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates through two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, interventional fluid management, pressure monitoring, and cardiac rhythm management, as well as thermodilution and pulmonary artery catheters and electrophysiology to treat various heart conditions. It also offers cardiovascular and critical care products to treat patients with life-threatening diseases, and protect healthcare providers from exposure to bloodborne pathogens. In addition, it provides interventional oncology and spine products to treat vertebral compression fractures, metastatic spinal tumors, liver cancer, uterine fibroids, benign prostatic hyperplasia, vertebral compression fractures, and arteriovenous malformations and hemostatic embolization, as well as breast cancer localization and guidance products for the treatment of breast cancer. Further, it offers non-vascular stents to treat pulmonary and gastrointestinal diseases; dilation balloons to endoscopically dilate strictures; and kits and accessories for endoscopy and bronchoscopy procedures. Additionally, it provides coated tubes and wires; microelectromechanical system sensor components; ConvertX nephroureteral stent system; and Fibrovein, a detergent-based sclerosant. The company sells its products to hospitals and clinic-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. The company was founded in 1987 and is headquartered in South Jordan, Utah. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/02 22:16
End of Day Share Price2020/07/02 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.